Literature DB >> 12607994

[Simultaneous development of factor V inhibitor and autoimmune thrombocytopenia in a patient with dermatomyositis].

Tomoiku Takaku1, Yuzuru Kuriyama, Nahoko Shoji, Masahiko Otawa, Akihiko Gotoh, Keisuke Miyazawa, Katsuyuki Fukutake, Kazuma Ohyashiki.   

Abstract

It has been previously demonstrated that aging, a history of malignancy or surgery, and exposure to bovine thrombin may be related to the presence of factor V inhibitor. However, dermatomyositis (DM) and autoimmune thrombocytopenic purpura (ATP) have rarely been associated with factor V inhibitor. Here we report a patient with factor V inhibitor accompanied by DM and ATP. In January 2000, a 77-year-old woman with DM was hospitalized because of susceptibility to bleeding. At the onset of DM, she had suffered from gastric leiomyosarcoma, and had undergone gastrectomy and splenectomy without the use of bovine thrombin. Thereafter, she had been treated with prednisolone until October 1999. On admission, prolongation of both APTT and PT was seen. Her factor V activity had fallen to 6%, and factor V inhibitor was positive at 8.9 Bethesda units. Moreover her platelet count had dropped to 1.0 x 10(9)/l. A bone marrow aspirate showed a cellular marrow with megakaryocytic hyperplasia, and the patient's PA-IgG level was elevated at 389 ng/10(7) cells. These findings suggested that ATP was also present. Additionally, the patient showed a positive result for Coombs test and consumption of complement. After a further course of steroid therapy, the patient's condition was markedly improved. This is a very rare case that showed factor V inhibitor and ATP simultaneously. Furthermore, the patient's clinical course suggests the relationship between the presence of factor V inhibitor and the reactivation of her collagen disease activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12607994

Source DB:  PubMed          Journal:  Rinsho Ketsueki        ISSN: 0485-1439


  3 in total

Review 1.  Acquired factor V inhibitors: a systematic review.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  J Thromb Thrombolysis       Date:  2011-05       Impact factor: 2.300

2.  Anti-Factor V inhibitor in patients with autoimmune diseases: case report and literature review.

Authors:  Shinsaku Imashuku; Takeshi Hasegawa; Kagekatsu Kubo; Masaki Nakato; Midori Shima
Journal:  Int Med Case Rep J       Date:  2011-04-20

3.  Acquired Factor V Inhibitor Complicated with Immune Thrombocytopenia.

Authors:  Fuka Mima; Ryota Minami; Mizuki Asako; Hitomi Matsunaga; Yuri Fujita; Yoshimi Takimoto; Sonoko Senda; Wataru Nakahara; Mako Ikeda; Shuji Ueda
Journal:  Intern Med       Date:  2021-06-26       Impact factor: 1.271

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.